Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Other Non-Current Liabilities (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $517000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 84.11% to $517000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $517000.0 through Dec 2025, down 84.11% year-over-year, with the annual reading at $517000.0 for FY2025, 84.11% down from the prior year.
  • Other Non-Current Liabilities hit $517000.0 in Q4 2025 for Lyell Immunopharma, down from $2.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $5.0 million in Q3 2021 to a low of $517000.0 in Q4 2025.
  • Historically, Other Non-Current Liabilities has averaged $3.5 million across 5 years, with a median of $3.7 million in 2023.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 758.27% in 2021 and later tumbled 84.11% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $4.6 million in 2021, then dropped by 9.92% to $4.1 million in 2022, then dropped by 10.92% to $3.7 million in 2023, then dropped by 11.22% to $3.3 million in 2024, then crashed by 84.11% to $517000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for LYEL at $517000.0 in Q4 2025, $2.7 million in Q3 2025, and $3.0 million in Q2 2025.